Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
FAST NEWS: CanSino Spends $21 Million on Share Buyback
The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) said Friday it bought back about 670,000 of its Shanghai-listed A-shares for 147 million yuan ($20.8 million) as of Nov. 30, accounting for…
RELATED ARTICLES
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Full Truck Alliance fires on all cylinders with strong earnings report
YMM.US
-
NEWS WRAP: Lianlian DigiTech’s revenue surges on payment network expansion
2598.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
